Table 2.
Patient demographics
| UCPPS with PSPS | UCPPS without PSPS | p-value | ||
|---|---|---|---|---|
| No. of participants (%) | 24 (30%) | 57 (70%) | ||
| Sex | Female | 19 (79%) | 29 (51%) | 0.025* |
| Male | 5 (21%) | 22 (49%) | ||
| Race | White | 24 (100%) | 50 (88%) | 0.098 |
| Black | 0 (0%) | 7 (12%) | ||
| Others | 0 (0%) | 0 (0%) | ||
| Ethnicity | Hispanic | 1 (4%) | 5 (9%) | 0.66 |
| Non-Hispanic | 23 (96%) | 52 (91%) | ||
| Mean age (SD) | 42.8 (14.3) | 49.1 (15.8) | 0.096 | |
| Mean duration of UCPPS symptoms in years (SD) | 9.1 (12.6) | 15.5 (12.8) | 0.163 | |
| Mean age of UCPPS symptom onset (SD) | 33.8 (17.6) | 35.0 (16.8) | 0.782 | |
| Interstitial cystitis symptom index, ICSI (SD) | 11.7 (5.1) | 8.8 (5.0) | 0.048* | |
| Interstitial cystitis problem index, ICPI (SD) | 10.3 (4.0) | 7.4 (4.6) | 0.026* | |
| Medications (no. of participants) | Elmiron | 12 | 19 | |
| Tricyclics | 11 | 16 | ||
| Antihistamines | 3 | 8 | ||
| Muscle relaxants | 3 | 2 | ||
| Narcotics | 5 | 3 | ||
| NSAIDs | 4 | 7 | ||
| Antiepileptics | 2 | 5 |